December 17, 2019

Cerevance Enters Research Collaboration with Takeda to Advance New Treatments for Gastrointestinal Disorders

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Boston, MA and Cambridge, UK – December 17, 2019 – Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has formed a multi-year research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) to identify novel target proteins expressed in the central nervous system and to develop new therapies against them for certain GI disorders. Scientists from the companies will select, confirm and validate targets from rich gene expression data sets generated by Cerevance’s NETSseq technology, which sorts and profiles specific neuronal and glial cell types in post-mortem human central nervous system tissue at unparalleled depth.

Under the terms of the agreement, which includes an upfront technology access fee and research support to Cerevance, Takeda will pay preclinical and clinical milestone payments and royalties to Cerevance as targets are validated and compounds are advanced through development and onto the market worldwide. Cerevance is eligible to receive development, commercialization and net sales-based milestone payments that may exceed $170 million on a per target basis.

“Through our new collaboration with Cerevance, we will access a highly innovative technology to identify new and unique targets for the treatment of GI disorders,” said Gareth Hicks, PhD, Head of the Gastrointestinal Drug Discovery Unit at Takeda. “We are excited to work with Cerevance scientists to drive forward our mission to provide new therapies for the highest unmet medical needs of patients with GI diseases.”

“We are thrilled to be collaborating with Takeda on this comprehensive effort to create novel therapies for patients suffering from GI disorders that can be targeted via modulation of CNS pathways,” said Mark Carlton, PhD, Chief Scientific Officer and co-founder of Cerevance. “The GI expertise of Takeda’s research organization is world renowned. We are looking forward to applying our powerful NETSseq CNS drug target identification platform to GI diseases with the Takeda team.”

About Cerevance

Cerevance is a private pharmaceutical company focused on central nervous system diseases. The company’s strengths include its powerful NETSseq target discovery platform, a large collection of human brain tissue samples, a pipeline of novel discovery-stage and clinical-stage compounds and a team with a proven track record. Its scientists believe that they are well positioned to deliver life-changing therapeutics for patients who have brain-related disorders. For additional information, please visit



Robert Middlebrook, +1-408-220-5722


Andrew Mielach,, +1- 646-876-5868